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Background: Quality audit and feedback to general practice is an important aspect of successful chronic disease
management. However, due to the complex temporal relationships associatedwith the nature of chronic illness,
formulating clinically relevant queries within the context of a speciﬁc evaluation period is difﬁcult.
Methods: We abstracted requirements from a set of previously developed criteria to develop a generic criteria
model thatcanbeusedto formulatequeries relatedtochronicconditionmanagement.Weimplementedandver-
iﬁed the framework, ChronoMedIt, to execute clinical queries within the scope of the criteria model.
Results: Our criteria model consists of four broad classes of audit criteria – lapse in indicated therapy, no
measurement recording, time toachieve target andmeasurementcontraindicating therapy.Using these cri-
teria classes as a guide, ChronoMedIt has been implemented as an extensible framework. ChronoMedIt can
produce criteria reports and has an integrated prescription and measurement timeline visualisation tool.
We illustrate the use of the framework by identifying patients on suboptimal therapy based on a range of
pre-determined audit criteria using production electronic medical record data from two general medical
practices for 607 and 679 patients with hypertension. As the most prominent result, we ﬁnd that 59%
(out of 607) and 34% (out of 679) of patients with hypertension had at least one episode of >30 day lapse
in their antihypertensive therapy over a 12-month evaluation period.
Conclusions: ChronoMedIt can reliably execute awide range of clinically useful queries to identify patients
whose chronic condition management can be improved.
 2009 Elsevier Inc. All rights reserved.1. Introduction consideration, such as the interactions between prescribing andAccording to the World Health Organization, chronic disease
was the leading cause of death worldwide in 2005 accounting for
around 35 million (or 60%) of the 58 million deaths [1]. It has been
projected that in 2015, 41 million (or 64%) out of all 64 million
deaths will be due to chronic illness [2]. This indicates that the bur-
den of chronic disease is a growing concern worldwide and any
incremental efforts to improve the management of chronic condi-
tions will have immense population health beneﬁts.
There are many facets to improving the management of patients
with chronic conditions. One such aspect is actively identifying pa-
tients who are (or have been) on suboptimal therapy and recalling
these patients to visit their general practitioners (‘‘GPs” in the Brit-
ish, Australian and New Zealand (NZ) systems; roughly equivalent
to US ‘‘family physicians”) who can then manage these patients
accordingly. However, identifying such patients poses a challenge
to GPs as the process involves taking various temporal aspects intoll rights reserved.
(T. Mabotuwana), jim@cs.classiﬁcation events.
As an introductory example, let us consider the domain of car-
diovascular disease (CVD) which is a leading contributor to chronic
disease related deaths [1]. It is estimated that CVD affects around
80 million Americans (36.3% of total population), out of which
73.6 million (or 33.3% of total population) are estimated to have
uncontrolled blood pressure (BP) [3]. The relationship between
BP and risk of CVD events is continuous, consistent and indepen-
dent of other risk factors – the higher the BP, the greater the chance
of having a heart attack, heart failure, stroke and kidney disease
[4]. Given the high prevalence and the CVD risk uncontrolled BP
poses, being able to identify patients who have had consecutively
high BPs over time, or patients who have not had a BP measure-
ment at all for a deﬁned period of time (say 90 days) after a high
BP measurement presents an opportunity to intervene in patients
whose clinical outcomes can be improved.
Attempts to improve patient adherence (also sometimes called
‘compliance’) to long-term medication can be considered another
important aspect of chronic disease management. Drugs are effec-
tive when taken as directed, yet low adherence to prescribed reg-
imens threatens their effectiveness in real-world use. Research has
shown that long-term adherence with medications for chronic
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nomic groups [5], and that the reasons for non-adherence are
poorly understood and vary with psychosocial factors [6]. Good
adherence to medication has been associated with positive
outcomes [7–9], and therefore, identifying patients with poor
adherence and intervening in these patients presents another
opportunity.
Despite the advances in electronic medical records, especially in
NZ where 99% of general practices use a speciﬁcally designed
computer-based patient management system (PMS) to assist with
recording of patient and clinical consultation details and to help
with the daily running of their business [10], identifying patients
on suboptimal therapy remains a challenge. Most PMSs provide
‘query-builder’ reporting functionalities used primarily for day-
to-day statistical and/or ﬁnancial reporting purposes; however, for-
mulating queries that require explicit treatment of temporal issues,
something that lies at theveryheart of chronicdiseasemanagement,
is often not readily supported. General practice electronic medical
record (EMR) data has been shown to have high completeness for
prescribed items (99.7%) and laboratory tests (100%) [11], providing
a good foundation for audit of chronic condition management in
accordance with evidence-based criteria. The primary objective of
this work is to develop a generic computational framework for
achieving sensitive and speciﬁc auditing directly from the EMR.
In the following sections we present a novel framework we
have developed – ChronoMedIt (Chronological Medical audIt) – a
framework that takes various temporal considerations into ac-
count when formulating and executing audit criteria as relevant
to chronic disease management. We outline our methodology
and framework requirements that were established during the de-
sign phase. In the results section we discuss details related to the
framework development, implementation and veriﬁcation fol-
lowed by how our framework has been used to identify speciﬁc co-
horts of patients that satisfy different audit criteria. We introduce a
prescription timeline visualisation mechanism we have developed
to aid clinicians in understanding patients’ individual prescribing
patterns along with criteria reports that can be produced using
the framework. We conclude with a discussion on how our frame-
work can be used in an active patient intervention and/or manage-
ment effort and possible future directions.2. Methodology
2.1. Related previous work
We collaborated with a NZ general medical practice that has pa-
tients from the ethnically diverse West Auckland suburbs. Hyper-
tension was the primary clinical domain of the study, and theTable 1
The eight quality improvement criteria (C1–C8) for patients with diagnosed hypertensio
angiotensin receptor blocker; eGFR, estimated glomerular ﬁltration rate.
Lack of persistence of medication; and/or lapsed BP recording
C1. A lapsea in AHT of >30 days and the lapse extends into the evaluation period (E
C2. A period of >180 days with no BP measurements extending into the EP
C3. A BP measurement of P160/100 mmHg followed by a gap of >120 days in BP m
Persistently high BP; lacking indicated therapy; and/or lab test contraindicating treat
C4. Three or more consistently high BP measurements (P160/100 mmHg) over 120
(i) the last of these high BPs was within the EP or
(ii) with no subsequent ‘‘controlled” BP (<160/100 mmHg) measurements after t
C5. Classiﬁed with diabetes mellitus and not on ACEi/ARB at any time during EP*
C6. Classiﬁed with myocardial infarction and not on beta-blocker at any time durin
C7. Classiﬁed with renal impairment and on ACEi/ARB and with eGFR <60 mL/min
C8. On thiazide(s) and with serum uric acid >0.42 mmol/l at any time during EP an
a i.e. a lapse of the indicated drug at some time during the EP and after the indicati
prescribing and subsequently taken as directed, would have run out (from [12]).ﬁrst stage of the study was developing a set of explicit audit crite-
ria to identify hypertensive patients who needed following up. The
presence of other conditions – notably, diabetes, myocardial infarc-
tion and renal impairment – complicates the treatment of hyper-
tension, and therefore such ‘comorbidity’ conditions feature in
the audit criteria. The researchers had a series of iterative discus-
sions with an expert panel from the general practice, including
the practice manager, three GPs and two nurses. The key ﬁndings
of these discussions were the eight explicit indicators of quality
improvement opportunities as shown in Table 1– details of the
development and evaluation of these criteria have been reported
elsewhere [12].
Note that in Table 1, ACEi/ARB, beta-blockers and thiazides are
drug classes commonly used to treat hypertension, while Allopuri-
nol and Colchicine are two speciﬁc drugs used to treat conditions
arising from excess uric acid (i.e., gout). eGFR gives an indication
on the state of the kidneys and is used to assess their excretory
function. ACEi/ARB is indicated for hypertensive patients classiﬁed
with diabetes [4,13] as these have the capacity to delay the onset
and progression of kidney disease and reduce other complications
of diabetes, such as foot ulcers and eye damage, as well as lowering
blood pressure [13]. Therefore it is important that patients with
hypertension complicated by diabetes are on continuous ACEi/
ARB medication. Similar medical reasoning can be found behind
the other quality indicators.2.2. Data extraction protocol
For our current work, we collaborated with two NZ general
practices – one was the same practice mentioned in Section 2.1
and the other was a general practice that was interested in our re-
search on quality audit reporting (we will refer to the former as
Practice-1 and the latter as Practice-2 hereafter). We extracted pa-
tient EMR data from the practices’ commercial PMSs, both being
MedTech32 [14], using MedTech32’s built-in query builder tool.
The study protocol was approved under the NZ Multiregional Eth-
ics Committee protocol number MEC/09/32/EXP and patient conﬁ-
dentiality was protected by withholding any identifying patient
details (such as name and address) from the University based
researchers. However, a practice-speciﬁc PMS internal identiﬁer
was provided to the researchers (e.g., ‘‘M004162”) so that the ex-
pert panel of clinicians working for the practice could still identify
the patients for clinical follow-up on their cases if required. The ex-
tracted dataset consisted of demographics (age in years, ethnicity
and gender), prescribing (but not dispensing) details, classiﬁca-
tions (diagnosis codes based on Read Clinical Codes [15], and some
procedure codes), relevant laboratory test results, and blood
pressure measurements. Our protocol was to extract data forn [12]. EP, Evaluation period; ACEi, angiotensin-converting enzyme inhibitor; ARB,
P)
easurements extending into the EP
ment
days or more where either
he consistently high BPs
g EP*
at any time during EP
d not on Allopurinol or Colchicine
ng diagnosis where a lapse is where a medication if ﬁrst dispensed on the day of
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classiﬁcations, which are relevant for an indeﬁnite time with re-
spect to chronic illness and hence were extracted for as far back
as possible. The dataset was then processed for the required crite-
ria in Table 1 using a traditional Structured Query Language (SQL)
based approach with multiple levels of nested/sub queries devel-
oped using an ad-hoc approach as detailed in [16].
2.3. The need for a novel criteria model
An inherent limitation of our past approaches [9,12,16] is that
the implementation was based on developing ad-hoc type queries
(irrespective of the querying technology used) to provide answers
to clinically important queries, but without the criteria being
grounded in an underlying criteria model. The lack of a criteria
model has the following disadvantages:
1. Interpretation of criteria formulated using natural language
may be ambiguous while a methodologically developed, well-
deﬁned criteria model promotes logically crisp interpretation.
2. Extending the existing set of criteria (per Table 1) becomes a
difﬁcult task and may require writing an entirely new query,
when it may have been possible to use a simple extension to
an existing criterion.
3. Veriﬁcation of criteria becomes a challenge as each individual
criterion needs to be veriﬁed accordingly. If common criteria
are present, verifying the common criteria once eliminates the
requirement to verify the common aspects of each speciﬁc cri-
terion (which requires a greater effort).
Therefore, it was required to develop a criteria model to over-
come these issues. The criteria presented in Table 1 were used as
exemplars to guide development of this new criteria model.
2.4. Framework requirements
The most important requirement of the framework to be devel-
oped was that it was to have the ﬂexibility to formulate a range of
audit criteria that could be easily extended as required. The frame-
work implementation was to closely follow the criteria model so
that any additional criteria to be modelled could be easily imple-
mented. Other requirements included:
 Criteria formulation using domain level therapeutic knowledge
– PMS systems usually do not have an inherent notion of a
drug class hierarchy. For example, simply because a particular
drug is an ACEi/ARB drug, a typical PMS cannot reason that this
is also an antihypertensive drug. Ad-hoc workarounds such as
using sub-queries are possible, but are error-prone and add
complexity.
 Criteria formulation using domain level classiﬁcation knowledge
– if we want to write a query that includes a concept such as
‘‘diabetes” using a reporting engine built-into a PMS, we need
to specify the explicit codes that constitute the concept diabetes
(as PMSs do not provide speciﬁc tables constituting only the
codes representing diabetes). Clinical coding systems (such as
Read Codes [15], ICD-10 [17] and SNOMED-CT [18]) tend to be
vast, and generally provide a wide array of codes for closely
related sets of concepts. For instance, the NZ Primary Health
Organisation (PHO) Performance Management Programme [19]
indicates 86 Read Clinical Codes to associate with a record of
diabetes.
 Using a shareable knowledge base (for drugs and classiﬁcation
details) – Clinical concepts such as hypertension or diabetes
are important domain-speciﬁc terms irrespective of the way
they are coded within a PMS. In NZ for example, Read ClinicalCodes Version 3 is widely used for coding patient classiﬁcations
in General Practice, while in Australian General Practice WON-
CA’s ICPC [20] is more popular. The US and the United Kingdom
(UK) favour ICD-9 and ICD-10, respectively, in general, but cod-
ing schemes can vary within regions as well. Therefore, having a
representation of domain-speciﬁc concepts (rather than system-
speciﬁc details) promotes shareability and reusability.
 Easy visualisation of knowledge base – Often with clinical
audits, statements such as ‘‘patients with hypertension. . .” (see
Table 1) can be seen, however, it is not always obvious exactly
what codes were used to deﬁne the condition (and hence what
speciﬁc patient cohort is being audited); thus, having an easy
visualisation/navigation capability is important.2.5. Framework veriﬁcation
Developing a medical audit framework on its own is not sufﬁ-
cient; as with any robust software system, it is important to devel-
op a mechanism to verify that framework output results are
accurate. Therefore, it was required to develop a scheme whereby
criteria output results could be veriﬁed. Our framework testing
methodology was three fold:
1. Develop two independent implementations (using different
algorithms) to determine patients satisfying a given criterion
so that the results from the two implementations can be
compared.
2. Develop test cases to perform boundary value analysis, equiva-
lence class testing and all-pairs testing for various test cases
that cover the breadth of possibilities resulting from the Criteria
Model that will be developed (as per Section 2.3). Refer to
[21,22] for details on these software testing techniques.
3. Perform random testing to ensure software reliability – Ade-
quately testing any software system of reasonable complexity
for all possible inputs requires a great effort and the number
of test cases required can easily become unmanageable. Random
testing is a form of software testing that refers to selecting test
inputs randomly from the input domain of a system [22]. Per-
forming random testing with a large number of test cases has
the potential to cover all possible combinations of the input
domain (with some probability for each combination to occur),
and has been suggested as a possible solution to ensure soft-
ware reliability [22,23]. A concept closely associated with gen-
erating random test cases is the operational proﬁle of the input
space [23,24] which is simply a set of disjoint (only one can
occur at a time) alternatives with the probability that each will
occur [24]. The operational proﬁle should take into account
usage patterns the software will encounter in its intended envi-
ronment. The argument here is that by testing according to the
usage, the failures found by imperfect methods are more likely
to be the important ones, that is, the ones most users would
ﬁrst encounter [23]. It has been suggested that when deﬁning
this proﬁle, a practically complete list of input variables from
the input space should be chosen [24], and therefore a suitable
domain-speciﬁc operation proﬁle was to be determined when
generating the test cases.3. Results
The key result of our work is an extensible computation frame-
work that can be used to formulate clinically important audit cri-
teria. In this section we will discuss how the computational
framework – ChronoMedIt has been developed to satisfy the
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based on production EMR data to demonstrate how the framework
has been used to identify patients who are on suboptimal therapy.3.1. The criteria model
Using the eight criteria in Table 1 as guidance on the require-
ments to engineer, we developed the generic criteria model using
the Uniﬁed Modelling Language (UML). Four broad, distinct criteria
classes (which we also refer to as elements) have been identiﬁed as
sufﬁcient to cover the requirements and the resulting UML model
is shown in Fig. 1. Note that the not on Allopurinol or Colchicine
clause in C8 in Table 1 has been ignored in the criteria engineering
effort. This is because discussions with the clinicians we collabo-
rate have indicated that patients having high serum uric acid levels
while on thiazides need to be identiﬁed irrespective of whether
they are on Allopurinol or Colchicine.
TheMedicationLapse element in Fig. 1 is used to formulate crite-
ria that are primarily related to medication adherence – i.e. a lapse
in indicated therapy. A lapse in medication is a period where the
patient is not covered by any medication provided that the pre-
scribed medication was dispensed and then consumed as directed
– various temporal issues need to be carefully considered within
the context of an evaluation period when identifying medication
lapses, and these have been reported elsewhere [25,26]. We have
discussed the importance of measuring medication adherence
using the concept of Medication Possession Ratio (MPR) previously
[9,25] – MPR is essentially a measure of the proportion-of-days-
covered by medication during a given EP. Although Table 1 does
not have a direct MPR related criterion, we have included the pos-
sibility to create adherence related measures in the Criteria Model
– for example, if we need to identify patients with MPR <80% (a
commonly used MPR threshold to identify patients with poor
adherence [27]), MedicationLapse can be speciﬁed using maxMPR-
Threshold = 80 and compareMaxMPRUsingOp = LESS_THAN. If min-
LapseDuration attribute was also set to 30, then it would mean
that patients need to not only satisfy MPR <80% constraint, but
should also have at least one episode of medication lapse of at least
30 days.Fig. 1. Elements of ChronoMedIt’s Criteria Model (using UML notation). Unless the mu
assumed (i.e. a compulsory attribute).The NoMeasurementRecording element is used to formulate que-
ries related to identifying lapse in measurement recording, such as
a lapse in BP measurement for over 180 days after being classiﬁed
with hypertension. The ConsecutivelyUncontrolledMeasurements
element contains parameters to identify consecutively uncon-
trolled measurements. This criterion is an indication of time to
achieve target, for example, if a patient has three or more consec-
utively high BPs over 180 days, then this indicates that the patient
has not achieved goal BP within a reasonable length of time. Meas-
ContraindicatingTherapy element is needed to determine patients
who have a lab test result that contraindicates therapy – for exam-
ple, treating patients with hypertension with thiazides may in-
crease serum uric acid levels, and it is important to either change
therapy or else prescribe medication to reduce this particular
side-effect.
All classes of criteria in Fig. 1 are derived from the CommonCri-
teria class which deﬁnes the basic properties of an audit report. The
importance of using a run-in period (deﬁned as an attribute in Com-
monCriteria) has been discussed previously [25,26] – essentially
this is a period just prior to the EP so that medication/measure-
ment coverages/lapses can be accurately accounted for. The after-
Classiﬁcations attribute is a means of specifying the classiﬁcations
the patients need to have – hypertension and diabetes, for exam-
ple. This has been speciﬁed as an optional attribute so that if we
need to identify patients who have consecutively high BPs, this
can be achieved irrespective of their classiﬁcation status. Our do-
main experience shows that in the particular practices with which
we are working, classiﬁcation details are fairly accurate in the pa-
tient EMR (i.e. almost all patients who have had consecutively high
BPs over time also have a corresponding hypertension classiﬁca-
tion), however, controlling BP is an important factor even if the pa-
tients do not have the formal ‘hypertension’ classiﬁcation.
The CommonMeasurementCriteria element contains attributes
that are related to measurements. There is provision to specify
two measurement threshold values along with corresponding
comparison operators. The ﬁrst is to be used for all measurement
values (such as eGFR for example) as well as systolic BP. Currently,
the only use of the second is to specify the diastolic BP threshold
when measurement type is BLOOD_PRESSURE.ltiplicity of a given attribute is speciﬁed ([0, 1] for example) a multiplicity of 1 is
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ﬁned as enumeration types within the model as shown in Fig. 2.
Attributes requiring a DrugsOrTherapy type in Fig. 1 can be speci-
ﬁed using generic drug names or by specifying a type of therapy
such as ‘Antihypertensives’. The Period type has been speciﬁed
using a start date and an end date.
We shall demonstrate (see Table 2) the use of attributes, ele-
ments and enumerations of the Criteria Model by formulating
the queries in Table 1 using the criteria elements shown in Fig. 1.
The evaluationPeriod and runInPeriod attributes are not shown as
these two are the same across all the criteria.
3.2. The computational framework
ChronoMedIt’s computational engine was developed using C#
.NET (we will refer to this simply as C# hereafter) to process theFig. 2. Some of the enumerations required for different criteria elements of
ChronoMedIt’s Criteria Model.
Table 2
Using elements from the Criteria Model to formulate Table 1 criteria.a
Criterion
(per Table 1)
Criteria Model element
(per Fig. 1)
C1 MedicationLapse
C2 NoMeasurementRecording
C3 NoMeasurementRecording
C4 ConsecutivelyUncontrolledMeasurements
C5 MedicationLapse
C6 MedicationLapse
C7 TherapyMeasurementOutOfTarget
C8 TherapyMeasurementOutOfTarget
a For C5 and C6, the compareMinLapseUsingOp does not need to be speciﬁed here as taudit criteria and identify the required patients. Microsoft SQL Ser-
ver 2008 was used to store the patient data. An overview of the
components of ChronoMedIt is shown in Fig. 3.
The Controllermodule in Fig. 3 communicates with the different
modules to manage the overall process. In the following sections
we shall describe the functionality of each of the other important
components.
3.2.1. Creating audit criteria
The Reporting Criteria and the Reporting Criteria Template to-
gether deﬁne the content and the structure of the reporting crite-
ria. The former is an Extensible Markup Language (XML) [28]
document containing speciﬁcs of the criteria while the latter is
an XML-Schema (XML-S) [29] document that speciﬁes the struc-
ture of the criteria according to the Criteria Model discussed previ-
ously in Section 3.1. The Criteria Parser module consists of two
main functional units – the XML-S Validator that validates the
XML document against the corresponding XML-S, and the XML Cri-
teria Parser that creates a C# representation of the criteria from the
XML document that can be processed by other C# modules. Note
that the latter is activated only if validation is successful.
3.2.2. The drug and classiﬁcation knowledge base
The Drug and Classiﬁcation Knowledge Base was modelled in the
Web Ontology Language (OWL) [30] using the Protégé-OWL [31]
development environment. OWL was chosen as the modelling lan-
guage due to several reasons – (i) the resulting knowledge base (inValues for Criteria Model element
(per Fig. 1)
afterClassiﬁcations = Hypertension
minLapseDuration = 30
compareMinLapseUsingOp = GREATER_THAN
lapseInDrugsOrThreapy = Antihypertensives
afterClassiﬁcations = Hypertension
measurementType = BLOOD_PRESSURE
minDaysWithoutMeasurement = 180
afterClassiﬁcations = Hypertension
measurementType = BLOOD_PRESSURE
measurementThreshold1 = 160
measurementThreshold1Using = GREATER_THAN
measurementThreshold2 = 100
measurementThreshold2Using = GREATER_THAN
minDaysWithoutMeasurement = 120
afterClassiﬁcations = Hypertension
measurementType = BLOOD_PRESSURE
measurementThreshold1 = 160
measurementThreshold1Using = GREATER_THAN
measurementThreshold2 = 100
measurementThreshold2Using = GREATER_THAN
minConsecUncontrolledMeas = 3
uncontrolledMeasOverMinDays = 120
afterClassiﬁcations = Hypertension and diabetes
minLapseDuration = 1
lapseInDrugsOrThreapy = ACEis or ARBs
afterClassiﬁcations = Hypertension and myocardial infarction
minLapseDuration = 1
lapseInDrugsOrThreapy = Beta-blockers
afterClassiﬁcations = Hypertension and renal impairment
measurementType = eGFR
measurementThreshold1 = 60
measurementThreshold1Using = LESS_THAN
lapseInDrugsOrThreapy = ACEis or ARBs
afterClassiﬁcations = Hypertension
measurementType = URIC_ACID
measurementThreshold1 = 0.42
measurementThreshold1Using = GREATER_THAN
lapseInDrugsOrThreapy = Thiazides
he default value of this attribute is set to GREATER_THAN_OR_EQUAL_TO.
Fig. 3. Components of ChronoMedIt.
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port for domain level modelling of therapeutic and classiﬁcation
knowledge (see Section 2.4 for domain level modelling require-
ments) and (iii) availability of free tools for (hierarchical) domain
level modelling and knowledge visualisation (Protégé-OWL in our
case).
The Drug Knowledge Base currently consists of antihypertensive,
antidepressant, antidiabetic and statin drugs (based on generic
names) and their corresponding drug classes, and is based on infor-
mation extracted from DrugDigest (http://www.drugdigest.org/).
During our data analysis stage, we identiﬁed cases where some
drugs were prescribed using popular brand names, instead of their
generic name, and we included several such brand names as well
into our knowledge base. The drug knowledge base consists of dif-
ferent drug classes such as ACEi/ARBs, diuretics and so on that are
collectively categorised under the drug class ‘‘Antihypertensives”,
leading to a drug class hierarchy (therefore a drug hierarchy since
each drug belongs to some drug class). The drug and classiﬁcation
information that was modelled using Protégé-OWL is shown in
Fig. 4.
Drug_Classes is a high-level concept under which different drug
classes have been created. Although our criteria per Table 1 are pri-
marily hypertension related, several other drug classes (such as
antidepressants) have been created in the drug knowledge base
(Fig. 4) simply for illustration purposes to indicate how the drug
ontology can be expanded to other domains. The Antihypertensives
class further reﬁnes to different subclasses of antihypertensive
medication. Similarly, the Problems class represents the different
classiﬁcations of interest – in this case we have included only dia-
betes, hypertension, renal impairement, myocardial infarction and
depression (depression has been included here so that a criterion
in a different domain, such as ‘‘patients with depression who have
a lapse >30 days in their antidepressant therapy” can be easily
authored if required). In NZ, the Read Clinical Codes are used to
classify patients, and the relevant Read Codes in our domain of
interest have been created in the Read_Codes class which is under
ClassiﬁcationSchemes. To indicate that a particular Read Code de-
notes a condition, the corresponding condition classes (Diabetes
and Renal_Impairement, for example, in the case of Read Code
C104.11 which indicates that a patient has diabetes and hence
developed renal impairment) is also made a parent class of thatRead Code (i.e. multiple inheritance). The grayish number within
parenthesis indicates the number of OWL individuals [30] in each
class – for example, ﬁve Read Codes are associated with hyperten-
sion (represented by the Hypertension class in the ontology).3.2.3. Implementation of the Criteria Model
All the methods required to implement the Criteria Model are
deﬁned in the ICriteriaManager interface (see Fig. 5.) that is deﬁned
within the Criteria Processor module. This ICriteriaManager inter-
face is the main accessor point to retrieve patients who satisfy a gi-
ven criterion. The GetPatientsSatisfyingCriterion(ICriterion criterion)
is the main method which accepts an instance of a criterion that
implements the ICriterion interface. Although not shown in Fig. 1,
all the criteria elements (MedicationLapse, NoMeasurementRecord-
ing for example) implement the simple ICriterion interface to pro-
vide a criterion speciﬁc implementation of the ICriterion interface
members. The GetPatientsSatisfyingCriterion method returns an ar-
ray of standard .NET DataTables and the number of tables the array
contains varies depending on the criterion of interest. If the crite-
rion was MedicationLapse with only a lapse or MPR speciﬁed, then
the resulting array will contain two DataTables, the ﬁrst one a list
of patients with corresponding lapse or MPR details and the second
one a table containing details related to the patient classiﬁcations.
If both lapse and MPR were speciﬁed, then the resulting array will
contain three DataTables – the ﬁrst will be lapse details, the second
will be MPR details and the third will be the classiﬁcation details.
Returning an array of standard .NET DataTables in this manner has
the key advantage of having query results in a consistent manner
irrespective of the criterion. If we used criteria speciﬁc data struc-
tures, then an end user will need to become familiar with these
data structures which requires a greater development effort. The
DataTables can then be used to present the data to a clinician in
a meaningful manner – for example, the underlying data sources
for the criteria reports we discuss in Section 3.2.4 are these
DataTables.
The ICriteriaManager interface in Fig. 5 also speciﬁes (but does
not implement) several helper methods (only two are shown in
the ﬁgure) where only the required parameters need to be passed
into the method to query for patients. These helper methods are
based on variations of the Criteria Model elements – for example,
Fig. 4. Two views of the drug and classiﬁcation knowledge base. Part of the Antihypertensives class is expanded in the left view and the Antidepressants and Problems classes
are expanded in the right view.
150 T. Mabotuwana, J. Warren / Journal of Biomedical Informatics 43 (2009) 144–158there are three helper methods (i.e. variations) for the Medication-
Lapse criterion – lapse only, MPR only and lapse and MPR.
The SQLCriteriaManager implementation (Fig. 5) is primarily
based on SQL Server stored procedures and functions and is the
main functional unit of the SQL Criteria Processor module in
Fig. 3. The SequentialCriteriaManager has a C# based procedural
implementation and forms the main functional unit of the Sequen-
tial Criteria Processor module in Fig. 3. As such, these two are inde-
pendent implementations of the Criteria Model that implement the
ICriteriaManager interface members. This type of implementation
reﬂects the Union design pattern in software engineering and is
based on polymorphism concepts of object oriented design.
3.2.4. Framework outputs
The two key outputs of ChronoMedIt are criteria reports and
prescription charts. Criteria reports are .pdf documents that are
generated using the .NET ReportViewer control by the Reporting
Client module shown in Fig. 3. The Reporting Client communicates
with the Criteria Processor and all reports are dependent on DataT-
able[] returned by the various ICriteriaManager methods. These re-
ports contain lists of patients with the relevant patient details that
are required to satisfy the criterion. For example, for a query such
as ‘patients classiﬁed with hypertension and diabetes who have an
MPR <80% with a lapse >30 days for ACEi/ARB medication for the
EP 01-May-2008 to 30-Apr-2009’ (which is similar to criteria C1
and C5 in Table 1), the relevant details for a selected patient are
shown in Fig. 6. The report indicates the different lapse durationsthat occurred during the speciﬁed EP, patient MPR (31.59%) as well
as the relevant patient classiﬁcation details.
Likewise, if our query was ‘a BP measurement of P160/
100 mmHg followed by a gap of >120 days in BP measurements
extending into the EP’ (i.e. C3 in Table 1), the resulting details for
a selected patient will be similar to that shown in Fig. 7. This report
indicates that there was no BP measurement for 133 days from 18-
Dec-2008 when a BP measurement of 165/107 was recorded for
patient TP86 who was diagnosed with hypertension on 21-Feb-
2006. In fact, in this particular case the patient has an on-going
lapse in BP measurement making this patient a very good candi-
date for a recall.
With most PMSs, the presentation of prescribed medication for
a patient is often in the form of a table where the prescriptions are
ordered chronologically. It is a challenge to identify patients with
prescribing lapses with this form of presentation. As a possible
solution, we developed a C# based graphical tool (this component
is represented by Prescribing Charts in Fig. 3) that can assist a clini-
cian to easily visualise patient prescribing patterns and also to
present some feedback to the patient if required in a more intuitive
and visually appealing manner. This was developed using some
freely available software written in Visual Basic .NET as a starting
point [32]. A clinician can enter the patient identiﬁer into the
framework which will produce the prescribing plot for that patient.
The Measurement Charts component in Fig. 3 is used to display
measurements such as BPs, eGFRs and so on. Fig. 8 shows such a
plot where the prescriptions and BP measurements are displayed
Fig. 5. Implementation of the Criteria Model using a SQL and sequential based approach. ‘[]’ represents an array of .NET DataTables.
Fig. 6. A patient entry in a MedicationLapse report.
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tients have been prescribed using a different colour for each
medication.
The prescriptions lists can be ﬁltered by selecting the required
drug or drug class using the drop-down menu in Fig. 8 (note that
‘All Drug Classes’ is selected; hence all prescriptions are shown).
If we use the ACE-Inhibitor ﬁlter, then we will see only the ACE-
Inhibitor prescriptions as shown in Fig. 9. Fig. 9 also shows how
hovering the mouse over a prescription shows the prescriptionduration and the different drug classes the drug belongs to. These
drug classes are based on the drug ontology discussed in Section
3.2.2 (also see Fig. 4). Similarly, the drop-down in the measure-
ments chart can be used to visualise eGFR, uric acid and other mea-
surements the patient has had.
It should be noted that the drug classes displayed in the drop-
down list are based on the drug ontology discussed previously in
Section 3.2.2. For example, cilazapril is shown under the ACE-
Inhibitor drug class in Fig. 4, which in turn is a sub class of antihy-
Fig. 7. A patient entry in a NoMeasurementRecording report.
Fig. 8. A prescribing and a BP measurement plot.
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scriptions with cilazapril will be shown (along with other
antihypertensives).3.2.5. Criteria processing with SQL or sequential implementation and
veriﬁcation of results
The nature of a SQL query is such that it will almost always re-
turn some result, unless there was an obvious syntax error (and is
almost certain to return a result via a visual query builder). There-
fore, it is necessary to verify that our SQL based implementation
produces the correct results. Software veriﬁcation usually refers
to evaluating a software system by determining whether the prod-
uct of a given development phase satisﬁes the requirements estab-
lished before the start of that phase and is about building the
product correctly [22].The independent SQL Criteria Processor and the Sequential Crite-
ria Processor implementations mentioned in Fig. 3 were used as a
solution for this. As mentioned previously, the SQL Criteria Proces-
sor uses a combination of SQL Server stored procedures and func-
tions to determine patient cohorts that satisfy a criterion while
the Sequential Criteria Processor uses a procedural based approach.
The essence of our veriﬁcation process is comparing the outputs of
these two modules and ensuring that the results the two different
implementations produce are the same. The Veriﬁer Results (which
reﬂects a system output) shown in Fig. 3 is representative of the
output from the SQL-Sequential Veriﬁermodule and contains details
of any discrepancies that may have occurred if veriﬁcation failed. A
run with failed veriﬁcation indicates an error somewhere, either in
the SQL or sequential implementation, or a patient case we have
not accounted for at all, hence each time veriﬁcation failed, the is-
Fig. 9. A prescribing chart ﬁltered by ACE-inhibitors.
Table 3
Operational proﬁle for various parameters in the input space.
Parameter Value/range
Number of prescriptions per patient [0, 10]
Duration of a prescription [15, 390]
Prescription issue date [01-Jan-08, 30-Jun-09]
Number of diagnoses per patient [0, 5]
Diagnoses date [01-Jan-05, 30-Jun-09]
Number of BP measurements per patient [0, 20]
Systolic BP value [80, 200]
Diastolic BP value [40, 140]a
BP measurement date [01-Jan-08, 30-Jun-09]
Number of eGFR measurements per patient [0, 8]
eGFR value [0, 120]
eGFR measurement date [01-Jan-08, 30-Jun-09]
Number of uric acid measurements per patient [0, 8]
Uric acid value [3, 10]
Uric acid measurement date [01-Jan-08, 30-Jun-09]
a It was ensured that the diastolic BP was lower than the corresponding systolic
BP.
Fig. 10. Operational proﬁle for prescription durations.
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relevant implementation was rectiﬁed. This was carried out as an
iterative process until both implementations resulted in the same
number of patients for a given criterion and satisﬁes our ﬁrst
framework veriﬁcation requirement per Section 2.5. In order to
satisfy our second veriﬁcation requirement, we have written a
number of test cases to perform boundary value analysis, equiva-
lence class testing and all-pairs testing for various test cases that
we have developed that cover the breadth of possibilities derived
from the Criteria Model (per Fig. 1). In the case of testing theMedi-
cationLapse implementation for patients with 30 day lapses, for
example, boundary value test cases test for lapse durations of 15,
29, 30, 31 and 45 days that overlap with the EP. Equivalence class
testing for this criterion looks at 45 day lapses (i.e. a nominal lapse)
that occur prior to the EP, during the EP and after the EP among
others. All-pairs testing considers multiple lapses a patient may
have – a lapse that ended prior to the EP with a lapse that occurs
during the EP for example, should result in only the lapse that oc-
curred during the EP being identiﬁed as a valid lapse. The ﬁnal
framework implementation has been tested against 169 different
cases based on these three different testing techniques. Refer to
[25,26] for various other temporal issues that need to be
considered.
In order to perform random testing (i.e. our third framework
veriﬁcation requirement) we developed a C# based random test pa-
tient generator (i.e. the Test Case Generator module in Fig. 3.) that
would generate a speciﬁed number of patients. We used the oper-
ational proﬁle shown in Table 3 to generate the test cases.
A period of 18 months was chosen for all parameters (except
classiﬁcations) as this is the duration we used in our EMR data
extraction protocol. For classiﬁcations we used 01-Jan-05 per Table
3. Values for all parameters except prescription duration were gen-
erated using a discrete uniform distribution. For a given range [a,
b], the discrete uniform distribution is given by:
f ðkÞ ¼
1
n ; a 6 k 6 b; n–0
0; otherwise
(
ð1Þ
where k denotes a discrete number out of the n possible values.
Prescriptions, however, are usually issued as 90-day scripts, and
therefore using a uniform distribution will not result in realistic
prescription durations. To better approximate this situation, a beta
distribution was used to determine the prescription durations with
a mode of 90 days. The beta distribution is a continuous probability
distribution deﬁned on the interval [0, 1] and parameterised by
two positive shape parameters, typically denoted by a and b. In or-
der to obtain the shape required to represent prescription dura-tions, these two parameters were set to 2 and 5, respectively.
The random numbers following this distribution on the interval
[0, 1] were generated using the NMath Core library available as a
.NET based component from CentreSpace [33].
Fig. 11. Executing the SQL and sequential based implementations for test cases and comparing results for a given criterion.
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the extra parameters deﬁning the minimum and maximum. The
mode m is then given by:
m ¼ aþ ðb aÞ a 1
aþ b 2 ð2Þ
The minimum duration of a script was set to be 15 days based on
experience with analysing production EMR prescribing data. When
m, a, a and b are set in Eq. (2), b results in 390 days which was then
used as the maximum duration for a given script. The generated
random numbers on the interval [0, 1] were then transformed to
[15, 390] using a linear transformation of [(390  15)x + 15] and
then rounded to the nearest day, which results in the distribution
shown in Fig. 10.
Based on what has been discussed thus far, we generated
100,000 random patients and created 41 different criteria repre-
senting the four key criteria classes in the Criteria Model. All three
types of framework veriﬁcation techniques were then carried out
using the steps shown in Fig. 11. A number of errors were identi-
ﬁed in both, the SQL and sequential based implementations during
this iterative veriﬁcation process which were subsequently
rectiﬁed.1 All NZ citizens and permanent residents can be enrolled with one PHO at a given
me and that PHO is funded for management of that person; general medical
ractices are then associated with PHOs.3.2.6. Identiﬁcation of patients on suboptimal therapy
We demonstrate the use of our framework using EMR data ex-
tracted (following the protocol discussed in Section 2.2) from the
two practices for the 18-month period from 01-Nov-2007 to 30-
Apr-2009 (with the exception of classiﬁcations which were ex-
tracted for as far back as possible). The EP was then deﬁned as
the one year period from 01-May-2008 to 30-Apr-2009 giving a
six month run-in period from 01-Nov-2007 to 30-Apr-2008. De-
tails of the two datasets are shown in Table 4.The practices we collaborate with were primarily interested in
funded patients enrolled at the practices, meaning that these pa-
tients are under the active management of the general practice1.
Therefore, only funded and enrolled patients classiﬁed with hyper-
tension (based on Read Clinical Codes) were included in our analysis.
The number of such patients was 607 and 679, respectively (see
Table 4).
Using the various attributes from the Criteria Model (as demon-
strated in Table 2), we formulated the criteria discussed previously
in Table 1 and the resulting numbers of patients are shown in
Table 5.4. Discussion
4.1. Signiﬁcance
In this paper we have presented a novel computational frame-
work that can be used to identify patients on long-termmedication
who are on suboptimal therapy. The generic framework we have
developed is ﬂexible, easily extensible and grounded in an under-
lying well-deﬁned Criteria Model. Our focus is on providing
practice-speciﬁc and/or patient-speciﬁc information to make it fea-
sible for practice staff to assess the quality of their management of
patients on long-termmedications over time. This may serve either
to support assessment of a quality improvement program or, by
examination of the speciﬁc cases exhibiting suboptimal manage-
ment, to act as a tool to support immediate follow-up on those pa-
tients. Furthermore, we have demonstrated the use of a newti
p
Table 4
Details of the two datasets extracted from practices.
Entity Practice-1 Practice-2
Number of patients 9009 21057
Number of prescriptions 95634 63269
Number of classiﬁcations 49894 46575
Number of funded and enrolled patients 5428 4258
Patients with hypertension 607 (11%) 679 (16%)
Antihypertensive prescriptions 10087 11623
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using high-level concepts across all the prescribed drug classes
(such as Antihypertensives, ACE-inhibitors, ARBs or antidepres-
sants). The tool can also be used to visualise various measure-
ments, such as BPs, making it potentially easier to understand
how a patient’s clinical outcomes have changed with therapy.
The nature of chronic illness requires reasoning on time inter-
vals, which are highly implicit in PMS databases that store time-
stamped events. Thus, capturing the clinical requirements neces-
sary to characterise good chronic disease management leads to
highly-complex and potentially error-prone queries. The imple-
mentation of the framework presented herein carefully takes var-
ious temporal considerations into account when identifying
patients on suboptimal therapy, and as such, can be used to cater
for such domain-speciﬁc querying requirements of quality
improvement for general practice activities. Using independent
implementations, we have veriﬁed that our results are accurate
and random testing has been performed on 100,000 test patients
to ensure software reliability. The criteria reports generated using
the framework not only give an overall indication of the number of
patients satisfying a given criterion, but also give details relevant
to each of the patients in the speciﬁc cohort.
Our framework uses an ontology based representation for drugs
and classiﬁcations, and a key advantage of using such an ontology
is the ability to cluster many transaction-level concepts into more
domain level (possibly hierarchical) concepts. Examples include
cilazapril drug being included under the ACEi/ARB drug class,
which in turn is under the antihypertensive medications; and the
Read Code G2.00 being associated with the domain level concept
‘hypertension’. This improves manageability and reusability of
the knowledge bases. The ontology based approach also allows
us to extend the domain of application of the framework; for
example, to expand the relevant classiﬁcation codes or medica-
tions by editing the knowledge bases in Protégé-OWL.
Our results based on production EMR data indicate that a signif-
icant portion (59% and 34%, respectively for the two practices con-
cerned) of patients with hypertension have >30 day lapses in their
antihypertensive medication. At least a ﬁfth of people with hyper-
tension have not had a BP measurement for >180 days while aTable 5
Number of patients classiﬁed with hypertension satisfying the eight audit criteria in Table
Criterion
C1 A lapse in AHT of >30 days and the lapse extends into the EP
C2 A period of >180 days with no BP measurements extending into the EP
C3 A BP measurement of P 160/100 mmHg followed by a gap of >120 days in
C4 Three or more consistently high BP measurements (P 160/100 mmHg) ove
(i) the last of these high BPs was within the EP or
(ii) with no subsequent ‘‘controlled” BP (<160/100 mmHg) measurements a
C5 Classiﬁed with diabetes mellitus and not on ACEi/ARB at any time during E
C6 Classiﬁed with myocardial infarction and not on beta-blocker at any time d
C7 Classiﬁed with renal impairment and on ACEi/ARB and with eGFR <60 mL/m
C8 On thiazide(s) and with serum uric acid >0.42 mmol/l at any time during Elarge proportion of patients (40% and 17%, respectively) with
hypertension and diabetes were not on ACEi/ARB medication. Each
of the other criteria accounts for 10% or less of the patients on sub-
optimal therapy, yet the patient numbers in Table 5 illustrate the
signiﬁcant opportunity for intervention to improve the chronic dis-
ease management process and thereby to improve patient
outcomes.
Three uses of this form of reporting for improvement of chronic
disease management are evident.
1. Awareness of immediate cases – identiﬁcation of those patients
that, at a particular moment in time, are out of supply of an
indicated medication. In the ﬁrst instance, the action is to treat
the non-adherence as inadvertent and recall the patient and/or
simply prescribe as indicated at the next opportunity. This
includes not just patients with lapsed medications, but also
those whose circumstances have changed (e.g., due to develop-
ment of a co-morbidity) and thus require additions to previous
therapy.
2. Opportunity for communication with those with poor supply
proﬁles – at some point it becomes logical to look to a lack of
concordance between doctor and patient, and/or to the ability
of the patient to achieve adherence for other reasons. Low
MPR over an extended time period and repeated lapses in med-
ication supply indicate the need for improved communication
between GP and patient; possibly the clinician needs to engage
the patient more in a joint ‘‘problem-solving” approach in rela-
tion to underlying adherence barriers.
3. Opportunity to critique GPs on their adherence to established
guidelines and compare practices on speciﬁed criteria – for
example, the JNC7 hypertension guideline [4] recommends
ACEi/ARB medication as compellingly indicated therapy for
patients with comorbid hypertension and chronic kidney dis-
ease. If an agreed set of audit criteria can be established, this
form of reporting also provides an opportunity to compare GP
practices (as we have done here with two practices) in an
attempt to provide feedback to the GPs to improve the manage-
ment of their patients with chronic conditions.
Preliminary result validation discussions with our GPs indicate
at least some medication lapses that occur due to GP errors, or at
least GP-system interaction errors, as opposed to patient factors.
For example, it is required to mark long-term medications as
‘Long-Term’ within the PMS, and if a GP has not marked a certain
medication as being long-term, and then at a later date the GP de-
cides to prescribe using the ‘‘prescribe all long-term medications”
feature of the PMS, the medications not marked as ‘Long-Term’ will
not be prescribed. As such, our reports had highlighted certain pa-
tients as having diabetes and not being on ACEi/ARB for over
30 days, but before a patient was recalled, the practice nurse had1.
Patients satisfying criterion
Practice-1
(N = 607)
Practice-2
(N = 679)
355 (59%) 230 (34%)
258 (43%) 136 (20%)
BP measurements extending into the EP 38 (6%) 15 (2%)
r 120 days or more where either
fter the consistently high BPs
5 (1%) 6 (1%)
P 240 (40%) 113 (17%)
uring EP 14 (2%) 22 (3%)
in at any time during EP 39 (6%) 21 (3%)
P 62 (10%) 15 (2%)
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curred due to a GP error rather than a patient error. This has been
a positive side-effect of our reporting.
Also, our GPs indicate that some difﬁcult/complex patients with
hypertension and diabetes routinely get sent to a ‘difﬁcult hyper-
tension clinic’ (such as [34]), but the only change in therapy the
specialist had to do was prescribe a diuretic or a statin (as indi-
cated in [34,35]). Specialist care is more expensive than primary
care and this type of issue can be identiﬁed at the GP level (using
variations of criteria discussed herein). Other than the higher costs
of referring to a specialist, there is the delay in optimisation of pa-
tient care; and it involves valuable specialist time, which ideally
should be spent seeing ‘truly difﬁcult’ cases.
4.2. Related work
Most PMSs have advanced reporting functionalities for day-to-
day reporting, but an important distinction between the approach
described herein and typical reporting capabilities is in the explicit
treatment of temporal issues, something that lies at the very heart
of chronic disease management. The recent Quality and Outcomes
Framework (QOF) in the UK [36], for example, is part of the General
Medical Services contract which encourages GPs to use evidence-
based interventions, particularly in the management of chronic
diseases (such as diabetes and hypertension). The QOF is in essence
an incentive payment system for the GPs and consists of many
quality indicators across ﬁve broad areas: clinical, organisational,
patient experience, additional services and holistic care. The clini-
cal domain consists of indicators for conditions including diabetes
and hypertension. The linking of the QOF directly to GP payment
and its clinical outcomes has had mixed reviews with [37,38]
reporting improvement in certain conditions while [39–41] have
viewed the whole scheme with more skepticism. Irrespective of
our opinion of the UK based implementation, we believe it is
important to give individual jurisdictions the ability to create their
own regional/local level indicators – for example, the Maori and
Paciﬁc Islander populations in NZ have inherently higher CVD risk,
all other factors being equal, than their European counterparts
[42]; thus, deﬁning a ‘controlled BP’ as 130/80 mmHg will be more
appropriate than the 145/85 mmHg level as used in the DM12 indi-
cator of the QOF.
Our developed criteria include identifying patients who need a
follow-up (e.g., ‘‘A lapse in AHT >30 days” criterion) which is re-
quired for sound adherence. Similarly, the QOF DM15 indicator re-
fers to ‘‘. . .patients with diabetes. . .who are treated with ACE-
inhibitors (or A2 antagonists)” but we argue that ‘‘treated with”
should be more tightly deﬁned in terms of persistence throughout
a speciﬁc evaluation period. Also, CHD6 is ‘‘. . .patients with coro-
nary heart disease [CHD] in whom the last blood pressure reading
(measured in the previous 15 months) is 150/90 or less”, but if a
patient with CHD had the last BP measurement (which was also
‘controlled’) almost 15 months ago, and then no BP measurement
at all, such a patient would satisfy CHD6, although the patient’s
BP may no longer be controlled. Therefore, to follow-up such pa-
tients, it is beneﬁcial to use a criterion similar to C2 in conjunction
with CHD6. It has been shown that introduction of the QOF was
associated with marked improvements in the management of cor-
onary heart disease in primary care in the UK [43], and we expect
our framework to be used in similar applications, but with some-
what different details depending on the site of implementation.
We have emphasised ﬂexibility in the parameters of adherence
queries to suit the range of guidelines and speciﬁc circumstances
under which clinical teams may wish to conduct clinical audit, as
well as in consideration of how much is yet to be learned about
interventions to improve adherence. We have created an XML doc-
ument format for queries to provide a transparent and standards-based interface to the architecture (along with the use of Protégé to
manage relevant concept taxonomies for drugs, problem classiﬁca-
tions and other supporting inputs such as BPs). Our work most clo-
sely resembles IDAN/KNAVE II framework [44,45] for temporal
abstraction on clinical data. However, we have taken a much nar-
rower focus that has allowed the majority of the work to be done
(after sufﬁcient conditioning of the data in our architecture)
through a set of domain-speciﬁc queries. Moreover, we have ex-
plored in greater detail the speciﬁc temporal issues around cohorts
of individuals over ﬁxed ‘evaluation periods’ while considering the
interplay of therapy and indications.
The Medical Database Adaptor (MEIDA) [46] is a framework
that is focussed on facilitating the use and reuse of decision sup-
port systems (DSSs) and knowledgebases with heterogeneous clin-
ical databases by overcoming the heterogeneity of the clinical
databases. The motivation behind this work was that often the
terms that one DSS uses to describe patient information is not
recognised (with the same interpretation) by another DSS or a local
clinical database. As a possible solution, MEIDA proposes a virtual
schema for patient data which enables interoperability between a
DSS knowledgebase and a given EMR structure. MEIDA uses stand-
ardised terminologies (such as ICD-9) to map between local data-
base terms and the virtual EMR, and the mapping process we
have used is somewhat similar, but more application speciﬁc –
we have used a ChronoMedIt speciﬁc schema to describe patient
data and then map details from the PMS data to our database dur-
ing the data extraction stage. MEIDA provides support to automate
the local database mapping process and as such if we can develop a
similar technique to eliminate the data extraction stage and work
directly with the PMS’s database, it will be beneﬁcial. However,
PMS vendors often have proprietary databases and providing such
close integration may be a challenge.
4.3. Limitations and future work
An important limitation of our identiﬁcation of patients is that
it is currently based on general practice prescribing data. As such,
the speciﬁc cases are those implied by the doctor–patient interac-
tions within a particular practice. For example, with medication
adherence/contra-indicated therapy (i.e. measurement out of tar-
get type criteria) issues, it is possible that patients receive prescrip-
tions or otherwise achieve medication supply through other
means. Therefore, our data provides no guarantee that prescribed
medication has been dispensed or subsequently consumed by the
patient as directed. Extension to include dispensing data, or even
home monitoring, would obviously result in superior ‘intelligence’
and is a desirable future direction. Another limitation of our com-
putational framework is that it is tailored to medications that are
taken regularly, in discrete, uniform doses. As such, the framework
is not presently sufﬁciently ﬁne-grained to assess adherence to
treatments where the patient adjusts the dose in response to con-
ditions, as with adjustment of insulin dosing based on blood sugar.
Further, we do not account for controlling outcomes such as BP by
means such as managing a patient’s diet and/or exercise.
Our discussions with practice clinicians indicate that CVD risk
(commonly termed CVR) is an important concept when identifying
‘at-risk’ patients – for example, patients with diabetes who have
CVR >15% with BP >130/80 mmHg. The Criteria Model currently
does not support this type of temporal relationships which needs
the BP measurement to be after a high CVR event and the required
diagnosis. However, this is a simple extension to the CommonMea-
surementCriteria class where the new derived criterion class will
need to specify the minimum required CVR threshold. As such,
extending the model to cater for such requirements is a straight-
forward task. For some patients the clinicians calculate CVR (either
manually, or via PREDICT – a decision support tool that is often
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dations to the GP and patient [47]), but currently we do not have
CVR information in our data extract. Extending ChronoMedIt to
either internally calculate CVR based on a suitable algorithm or
extending our data extraction protocol to include CVR information
may be a potential solution for this.
Beyond expansion of the data analysis framework per se, an
immediate future direction of this work is to develop an end user
application (targeting a clinician or a practice manager for exam-
ple) where the various parameters required to formulate a crite-
rion can be speciﬁed via a user-friendly graphical user interface.
The framework already has well-deﬁned input-output relation-
ships for the criteria; an interface could be developed as a stand-
alone desktop application or as a web service. We are also
considering developing a Clinical Document Architecture (CDA)
[48] based speciﬁcation for ChronoMedIt’s patient data structure
so that PMSs with CDA support could use the auditing functional-
ities of ChronoMedIt. Another immediate future work programme
is to investigate the issues associated with those patients who are
on suboptimal therapy. Our framework does not inherently pro-
vide any solution with respect to how the information is to be used
by a practice to address the issues. Currently, we have received
funding from the Health Research Council in New Zealand to carry
out a feasibility study of nurse led intervention on patients identi-
ﬁed as having low antihypertensive medication possession using
ChronoMedIt. Expansion of this approach to address a broader
range of criteria (consistently high BPs, for example) will be con-
sidered in due course.5. Conclusions
The computational framework we have developed – ChronoM-
edIt – shows potential to be used as a tool to improve clinical out-
comes. Our framework supports analysis of practice EMRs with
consideration of various non-trivial temporal relations between
prescriptions, measurements and problem classiﬁcation within
the context of a speciﬁed EP. Further work is needed both to ex-
pand the EMR-based reporting to various other important classes
of quality audit criteria for chronic condition management and to
determine how to effectively utilise such reporting to improve pa-
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